1. Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). (17th January 2020) Authors: Iwata, Hiroji; Inoue, Kenichi; Kaneko, Koji; Ito, Yoshinori; Tsugawa, Koichiro; Hasegawa, Ayumi; Nakagawa, Shintaro; Kuratomi, Hiroyasu; Tamura, Kenji Journal: Japanese journal of clinical oncology Issue: Volume 50:Number 2(2020) Page Start: 223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). (15th October 2019) Authors: Iwata, Hiroji; Inoue, Kenichi; Kaneko, Koji; Ito, Yoshinori; Tsugawa, Koichiro; Hasegawa, Ayumi; Nakagawa, Shintaro; Kuratomi, Hiroyasu; Tamura, Kenji Journal: Japanese journal of clinical oncology Issue: Volume 49:Number 12(2019) Page Start: 1083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗